Filing Flows › IGC Pharma (IGC) › Q2 2026 › vs Q1 2026
IGC Pharma (IGC) Q2 2026 vs Q1 2026 (quarter over quarter)
IGC Pharma's revenue fell $52K (-16%) from $317K in Q1 2026 to $265K in Q2 2026. The biggest changes: White Labeling Services −$38K (-13%); Wellness and Lifestyle −$14K (-61%).
IGC Pharma, Q2 2026: revenue $265K (-19% year over year), net loss $2.9M, operating cash flow −$1.4M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| White Labeling Services | $256K | $294K | −$38K | -13% |
| Wellness and Lifestyle | $9K | $23K | −$14K | -61% |
| Revenue | $265K | $317K | −$52K | -16% |
| Net loss | $2.9M | $2.4M | $534K | +22% |
| Costs & expenses | $3.2M | $2.8M | $426K | +15% |
| Operating costs | $3.0M | $2.8M | $274K | +10% |
| Interest & other, net | $152K | −$56K | $208K | — |
| Cost of revenue | $217K | $262K | −$45K | -17% |
| Research & development | $1.4M | $1.3M | $118K | +9% |
| SG&A | $1.4M | $1.2M | $201K | +16% |
| Operating cash sources | $2.9M | $2.4M | $534K | +22% |
| Depreciation & amortization | $56K | $58K | −$2K | -3% |
| Share-based compensation | $200K | $4.0M | −$3.8M | -95% |
| Working capital & other | $1.3M | −$2.9M | $4.2M | — |
| Cash used in operations | $1.4M | $1.2M | $127K | +10% |
| Net loss absorbed | $2.9M | $2.4M | $534K | +22% |
Questions
How much did IGC Pharma's revenue grow quarter over quarter in Q2 2026?
IGC Pharma's revenue fell $52K (-16%) from $317K in Q1 2026 to $265K in Q2 2026.
What drove IGC Pharma's revenue change in Q2 2026?
White Labeling Services −$38K (-13%); Wellness and Lifestyle −$14K (-61%).